🔗 Visit the ClinicalTrials.gov page for NCT00542451
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. | J Clin Oncol | 2014 | 2.82 |
| 2 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. | N Engl J Med | 2015 | 1.76 |
| 3 | MYC in breast tumor progression. | Expert Rev Anticancer Ther | 2008 | 1.49 |
| 4 | Treatment of HER2-positive breast cancer. | Breast | 2013 | 1.09 |
| 5 | Trastuzumab for small HER-2+ breast cancer: small tumor, big decision. | Oncologist | 2012 | 1.08 |
| 6 | HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. | Cancer Med | 2014 | 0.86 |
| 7 | Targeted Therapy for Early and Locally Advanced Breast Cancer. | Breast Care (Basel) | 2010 | 0.78 |